Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2004 1
2005 1
2006 3
2007 2
2008 3
2009 2
2010 1
2011 2
2012 3
2013 3
2014 2
2015 1
2016 2
2018 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions.
Rivenbark AG, Livasy CA, Boyd CE, Keppler D, Coleman WB. Rivenbark AG, et al. Exp Mol Pathol. 2007 Oct;83(2):188-97. doi: 10.1016/j.yexmp.2007.03.008. Epub 2007 Apr 18. Exp Mol Pathol. 2007. PMID: 17540367 Free PMC article.
In most cases (12/23, 52%), the expression of cystatin M directly reflected CST6 promoter methylation status. In remaining lesions (8/23, 35%) loss of cystatin M was not associated with CST6 promoter hypermethylation, indicating that other mechanisms can account for …
In most cases (12/23, 52%), the expression of cystatin M directly reflected CST6 promoter methylation status. In remaining lesions (8 …
CST6 promoter methylation in circulating cell-free DNA of breast cancer patients.
Chimonidou M, Tzitzira A, Strati A, Sotiropoulou G, Sfikas C, Malamos N, Georgoulias V, Lianidou E. Chimonidou M, et al. Clin Biochem. 2013 Feb;46(3):235-40. doi: 10.1016/j.clinbiochem.2012.09.015. Epub 2012 Sep 21. Clin Biochem. 2013. PMID: 23006792
OBJECTIVES: We have recently shown that detection of CST6 promoter methylation in primary breast tumors can provide important prognostic information in patients with operable breast cancer and that CST6 promoter is also methylated in Circulating Tumor Cells (CTC). . …
OBJECTIVES: We have recently shown that detection of CST6 promoter methylation in primary breast tumors can provide important prognos …
DNA methylation-dependent silencing of CST6 in human breast cancer cell lines.
Rivenbark AG, Jones WD, Coleman WB. Rivenbark AG, et al. Lab Invest. 2006 Dec;86(12):1233-42. doi: 10.1038/labinvest.3700485. Epub 2006 Oct 16. Lab Invest. 2006. PMID: 17043665 Free article.
Bisulfite sequencing of CST6 in a subset of breast cancer cell lines revealed CpG island hypermethylation in CST6-negative cells, and an absence of CpG island methylation in cells that express CST6. ...These results establish a strong link between CST6 …
Bisulfite sequencing of CST6 in a subset of breast cancer cell lines revealed CpG island hypermethylation in CST6-negative cel …
TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities.
D'Costa ZC, Higgins C, Ong CW, Irwin GW, Boyle D, McArt DG, McCloskey K, Buckley NE, Crawford NT, Thiagarajan L, Murray JT, Kennedy RD, Mulligan KA, Harkin DP, Waugh DJ, Scott CJ, Salto-Tellez M, Williams R, Mullan PB. D'Costa ZC, et al. Oncotarget. 2014 Mar 30;5(6):1609-20. doi: 10.18632/oncotarget.1707. Oncotarget. 2014. PMID: 24742492 Free PMC article.
CST6 did not require secretion or glycosylation to elicit its cell killing effects, suggesting an intracellular mode of action. ...We have also noted that tumors with altered TBX2/CST6 expression show poor overall survival. This novel TBX2-CST6-LGMN signaling …
CST6 did not require secretion or glycosylation to elicit its cell killing effects, suggesting an intracellular mode of action. ...We …
TBX2 acts as a potent transcriptional silencer of tumour suppressor genes through interaction with the CoREST complex to sustain the proliferation of breast cancers.
McIntyre AJ, Angel CZ, Smith JS, Templeman A, Beattie K, Beattie S, Ormrod A, Devlin E, McGreevy C, Bothwell C, Eddie SL, Buckley NE, Williams R, Mullan PB. McIntyre AJ, et al. Nucleic Acids Res. 2022 Jun 24;50(11):6154-6173. doi: 10.1093/nar/gkac494. Nucleic Acids Res. 2022. PMID: 35687133 Free PMC article.
TBX2 is an anti-senescence gene, promoting cell growth and survival through repression of Tumour Suppressor Genes (TSGs), such as NDRG1 and CST6. Previously we found that TBX2 cooperates with the PRC2 complex to repress several TSGs, and that PRC2 inhibition restored NDRG1 …
TBX2 is an anti-senescence gene, promoting cell growth and survival through repression of Tumour Suppressor Genes (TSGs), such as NDRG1 and …
A closed-tube methylation-sensitive high resolution melting assay (MS-HRMA) for the semi-quantitative determination of CST6 promoter methylation in clinical samples.
Dimitrakopoulos L, Vorkas PA, Georgoulias V, Lianidou ES. Dimitrakopoulos L, et al. BMC Cancer. 2012 Oct 22;12:486. doi: 10.1186/1471-2407-12-486. BMC Cancer. 2012. PMID: 23088560 Free PMC article.
RESULTS: The developed assay is highly specific and sensitive since it can detect the presence of 1% methylated CST6 sequence and provides additionally a semi-quantitative estimation of CST6 promoter methylation. CST6 promoter was methylated in 39/80 (48.75%) …
RESULTS: The developed assay is highly specific and sensitive since it can detect the presence of 1% methylated CST6 sequence and pro …
DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells.
Chimonidou M, Strati A, Tzitzira A, Sotiropoulou G, Malamos N, Georgoulias V, Lianidou ES. Chimonidou M, et al. Clin Chem. 2011 Aug;57(8):1169-77. doi: 10.1373/clinchem.2011.165902. Epub 2011 Jun 23. Clin Chem. 2011. PMID: 21700955
RESULTS: In CTCs of patients with operable breast cancer, promoter methylation of CST6 was observed in 17.9%, BRMS1 in 32.1%, and SOX17 in 53.6% of patients. In CTCs of patients with verified metastasis, promoter methylation of CST6 was observed in 37.0%, BRMS1 in 4 …
RESULTS: In CTCs of patients with operable breast cancer, promoter methylation of CST6 was observed in 17.9%, BRMS1 in 32.1%, and SOX …
Development and validation of a multiplex methylation specific PCR-coupled liquid bead array for liquid biopsy analysis.
Parisi C, Mastoraki S, Markou A, Strati A, Chimonidou M, Georgoulias V, Lianidou ES. Parisi C, et al. Clin Chim Acta. 2016 Oct 1;461:156-64. doi: 10.1016/j.cca.2016.08.003. Epub 2016 Aug 7. Clin Chim Acta. 2016. PMID: 27510924
RESULTS: In the EpCAM-positive CTCs fraction we observed methylation of: a) CST6, in 11/30(37%) and 11/30(37%), b) BRMS1 in 8/30(27%) and 11/30(37%) c) SOX17 in 8/30(27%) and 13/30(43%) early breast cancer patients and patients with verified metastasis respectively. In ctD …
RESULTS: In the EpCAM-positive CTCs fraction we observed methylation of: a) CST6, in 11/30(37%) and 11/30(37%), b) BRMS1 in 8/30(27%) …
Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
Roll JD, Rivenbark AG, Sandhu R, Parker JS, Jones WD, Carey LA, Livasy CA, Coleman WB. Roll JD, et al. Exp Mol Pathol. 2013 Dec;95(3):276-87. doi: 10.1016/j.yexmp.2013.09.001. Epub 2013 Sep 14. Exp Mol Pathol. 2013. PMID: 24045095
The objective of this study was to determine if this aberrant DNA hypermethylation (i) is found in primary breast cancers, (ii) is associated with specific breast cancer molecular subtypes, and (iii) influences patient outcomes. Analysis of epigenetic biomarker genes (CDH1, CEACA …
The objective of this study was to determine if this aberrant DNA hypermethylation (i) is found in primary breast cancers, (ii) is associate …
Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer.
Kioulafa M, Balkouranidou I, Sotiropoulou G, Kaklamanis L, Mavroudis D, Georgoulias V, Lianidou ES. Kioulafa M, et al. Int J Cancer. 2009 Dec 15;125(12):2887-92. doi: 10.1002/ijc.24686. Int J Cancer. 2009. PMID: 19551853 Free article.
The methylation status of cystatin M (CST6) gene in breast tumors was investigated and its prognostic significance as a novel breast cancer biomarker was evaluated. ...CST6 was rarely methylated in the normal tissue surrounding the tumor (10%). ...
The methylation status of cystatin M (CST6) gene in breast tumors was investigated and its prognostic significance as a novel breast …
26 results